Cybin to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Published on July 27, 2023

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023 in Boston, MA.

Mr. Drysdale’s fireside chat will be webcast live on Thursday, August 10, 2023 at 11:00 a.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

 

Continue reading on website
Other news

Prime Minister Announces Changes to the Ministry

July 26, 2023
The Prime Minister, Justin Trudeau, today announced changes to the Ministry. The new Ministry, adding to a strong core economic team, is ready to deliver on what matters most to Canadians: making life more affordable for the middle class, growing the economy, and building a strong future for people from coast to coast to coast.Building on the work done since 2015 to invest in Canadians and to stre

Roche loses spark for gene therapy, axing hemophilia A candidate from pipeline

July 27, 2023
Roche’s gene therapy ambitions have taken another blow. Shortly after writing down (PDF) the value of one of Spark Therapeutics’ hemophilia A candidates, the Swiss drugmaker has removed a second therapy aimed at the disease from its midphase pipeline.Buying Spark for $4.3 billion in 2019 gave Roche control of hemophilia A gene therapies that could have posed a threat to its existing drug Hemlibra.